About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 34417960 Journal: Clinical & Translational Oncology Year: 2022 Reference: Clin Transl Oncol. 2022 Feb;24(2):388-392. doi: 10.1007/s12094-021-02693-8. Epub 2021 Aug 21. Impact factor: 3.405 Publication type: Paper in international publication Authors: Diaz-de-Heredia, C, Carrasco, E, Uria Oficialdegui, M L, Murillo-Sanjuan, L, Balmana, J, de Pablo Garcia-Cuenca, A, Lorente Guerrero, J et al. DOI: 10.1007/s12094-021-02693-8
PMID: 34807782 Journal: Expert Opinion on Drug Discovery Year: 2022 Reference: Expert Opin Drug Discov. 2022 Feb;17(2):167-179. doi: 10.1080/17460441.2022.2002297. Epub 2021 Nov 22. Impact factor: 6.098 Publication type: Review in international publication Authors: Segura, Miguel F, Soriano, Aroa, Roma, Josep, Piskareva, Olga, Jimenez, Carlos, Boloix, Ariadna, Fletcher, Jamie I, Haber, Michelle, Gray, Juliet C, Cerda-Alberich, Leonor et al. DOI: 10.1080/17460441.2022.2002297
PMID: 34786859 Journal: Small Year: 2022 Reference: Small. 2022 Jan;18(3):e2101959. doi: 10.1002/smll.202101959. Epub 2021 Nov 16. Impact factor: 13.281 Publication type: Paper in international publication Authors: de Toledo, Josep Sanchez, Gallego, Soledad, Veciana, Jaume, Albertazzi, Lorenzo, Segura, Miguel F, Ventosa, Nora, Sala, Santi, Cordoba, Alba, Foradada, Laia, Boloix, Ariadna et al. DOI: 10.1002/smll.202101959
PMID: 35029330 Journal: PEDIATRIC BLOOD & CANCER Year: 2022 Reference: Pediatr Blood Cancer. 2022 Aug;69(8):e29551. doi: 10.1002/pbc.29551. Epub 2022 Jan 14. Impact factor: 3.167 Publication type: Paper in international publication Authors: Cortes, Marta, Carceller, Fernando, Rubio-San-Simon, Alba, Vaidya, Sucheta J, Bautista, Francisco, Moreno, Lucas et al. DOI: 10.1002/pbc.29551
PMID: 33067614 Journal: BLOOD Year: 2021 Reference: Blood. 2021 Mar 25;137(12):1582-1590. doi: 10.1182/blood.2020007848. Impact factor: 23.629 Publication type: Paper in international publication Authors: Brivio, Erica, Locatelli, Franco, Lopez-Yurda, Marta, Malone, Andrea, Diaz de Heredia, Cristina, Bielorai, Bella, Rossig, Claudia, van der Velden, Vincent H J, Ammerlaan, Anneke Cj, Thano, Adriana et al. DOI: 10.1182/blood.2020007848
PMID: 33742757 Journal: PEDIATRIC TRANSPLANTATION Year: 2021 Reference: Pediatr Transplant. 2021 Jun;25(4):e14010. doi: 10.1111/petr.14010. Epub 2021 Mar 20. Impact factor: 1.502 Publication type: Letter whit IF Authors: Uria-Oficialdegui, M Luz, Alonso, Laura, Benitez-Carabante, M Isabel, Renedo, Berta, Oliveras, Maria, Diaz-de-Heredia, Cristina et al. DOI: 10.1111/petr.14010
PMID: 33718801 Journal: HemaSphere Year: 2021 Reference: Hemasphere. 2021 Mar 9;5(4):e539. doi: 10.1097/HS9.0000000000000539. eCollection 2021 Apr. Impact factor: 0 Publication type: Paper in international publication Authors: Rio, Paula, Galvez, Eva, Vallespin, Elena, Arias-Salgado, Elena G, Sanchez-Valdepenas, Carmen, Gimenez, Yari, Navarro, Susana, Peiro, Montserrat, Nevado, Julian, Zubicaray, Josune et al. DOI: 10.1097/HS9.0000000000000539
PMID: 32229130 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2021 Reference: Enferm Infecc Microbiol Clin. 2021 Mar;39(3):134-138. doi: 10.1016/j.eimc.2020.02.015. Epub 2020 Mar 27. Impact factor: 1.731 Publication type: Paper in national publication Authors: Melendo, Susana, Fernandez-Polo, Aurora, Castellnou Asens, Ivette, Mendoza-Palomar, Natalia, Barnes-Mayolas, Meritxell, Soler-Palacin, Pere, Soler Palacin, Pere, Melendo Perez, Susana, Mendoza Palomar, Natalia, Nieves Larrosa Escartin, M et al. DOI: 10.1016/j.eimc.2020.02.015
PMID: 32203264 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Sep;55(9):1796-1809. doi: 10.1038/s41409-020-0863-z. Epub 2020 Mar 19. Impact factor: 4.725 Publication type: Review in international publication Authors: Pochon, Cecile, Menconi, Maria Cristina, Bosman, Paul, Mauro, Margherita, Tridello, Gloria, de Latour, Regis Peffault, Dufour, Carlo, Afanasyev, Boris, Stein, Jerry, Krivan, Gergely et al. DOI: 10.1038/s41409-020-0863-z
PMID: 32179448 Journal: EUROPEAN JOURNAL OF CANCER Year: 2020 Reference: Eur J Cancer. 2020 May;130:72-80. doi: 10.1016/j.ejca.2020.01.029. Epub 2020 Mar 13. Impact factor: 7.275 Publication type: Paper in international publication Authors: Ferrari, Andrea, Merks, Johannes H M, Chisholm, Julia C, Orbach, Daniel, Brennan, Bernadette, Gallego, Soledad, van Noesel, Max M, McHugh, Kieran, van Rijn, Rick R, Gaze, Mark N et al. DOI: 10.1016/j.ejca.2020.01.029
PMID: 32133691 Journal: TRANSPLANT INTERNATIONAL Year: 2020 Reference: Transpl Int. 2020 Jul;33(7):762-772. doi: 10.1111/tri.13601. Epub 2020 Apr 2. Impact factor: 3.177 Publication type: Paper in international publication Authors: Lawitschka, A, Dalle, J-H, Balduzzi, A, Gibson, B, Diaz De Heredia, C, Wachowiak, J, Dalissier, A, Vettenranta, K, Yaniv, I, Bordon, V et al. DOI: 10.1111/tri.13601
PMID: 32142919 Journal: CANCER LETTERS Year: 2020 Reference: Cancer Lett. 2020 May 1;477:49-59. doi: 10.1016/j.canlet.2020.02.035. Epub 2020 Mar 3. Impact factor: 7.36 Publication type: Paper in international publication Authors: Molist, C, Navarro, N, Giralt, I, Zarzosa, P, Gallo-Oller, G, Pons, G, Magdaleno, A, Moreno, L, Guillen, G, Hladun, R et al. DOI: 10.1016/j.canlet.2020.02.035
The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.
Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.
La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.
